>
Dexcom Inc logo

DXCM - Dexcom Inc Share Price

$388.5 1.4  0.3%

Last Trade - 3:04pm

Sector
Healthcare
Size
Large Cap
Market Cap £27.25bn
Enterprise Value £26.53bn
Revenue £1.40bn
Position in Universe 336th / 6841
Bullish
Bearish
Unlock DXCM Revenue
Momentum
Relative Strength (%)
1m +4.03%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -15.1%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
145.2
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
402 573.3 718.5 1,032 1,476 1,927 2,324 2,797 +36.8%
+295.5 -55.7 +43.8
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, DexCom,Inc. revenues increased 31% to $1.93B. Net income increasedfrom $101.1M to $493.6M. Revenues reflect United Statessegment increase of 30% to $1.51B, Outside of United statessegment increase of 33% to $417.2M. Net income benefitedfrom Income (loss) from equity investments decrease from$4.2M (expense) to $0K. Basic Earnings per Share excludingExtraordinary Items increased from $1.11 to $5.23.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for DXCM
Graphical History

Revenue

DXCM Revenue Unlock DXCM Revenue

Net Income

DXCM Net Income Unlock DXCM Revenue

Normalised EPS

DXCM Normalised EPS Unlock DXCM Revenue

PE Ratio Range

DXCM PE Ratio Range Unlock DXCM Revenue

Dividend Yield Range

DXCM Dividend Yield Range Unlock DXCM Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
DXCM EPS Forecasts Unlock DXCM Revenue
Profile Summary

Dexcom, Inc. is a medical device company. The Company is primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for use by people with diabetes and by healthcare providers. Its products include Dexcom G6 and Dexcom Share. The G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an app on the patient’s iPhone, iPod touch, iPad or Android mobile device to securely and wirelessly transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients, who can remotely monitor a patient’s glucose information and receive alert notifications.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated May 13, 1999
Public Since April 14, 2005
No. of Shareholders: 40
No. of Employees: 5,500
Sector Healthcare
Industry Healthcare Equipment & Supplies
Index Nasdaq Composite , Nasdaq 100 , S&P Composite 1500 , S&P 500 , S&P 500 Health Care (sector),
Exchange NASDAQ Global Select Market
Shares in Issue 96,705,867
Free Float (0.0%)
Eligible for
ISAs
SIPPs
DXCM Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for DXCM
Upcoming Events for DXCM
Thursday 29th April, 2021
Q1 2021 DexCom Inc Earnings Release
Thursday 29th April, 2021
Q1 2021 Dexcom Inc Earnings Call
Friday 21st May, 2021 Estimate
DexCom Inc Annual Shareholders Meeting
Monday 26th July, 2021 Estimate
Q2 2021 DexCom Inc Earnings Release
Frequently Asked Questions for Dexcom Inc
What is the Dexcom Inc share price?

As of 3:04pm, shares in Dexcom Inc are trading at $388.5, giving the company a market capitalisation of £27.25bn. This share price information is delayed by 15 minutes.

How has the Dexcom Inc share price performed this year?

Shares in Dexcom Inc are currently trading at $388.5 and the price has moved by 40.64% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Dexcom Inc price has moved by -5.93% over the past year.

What are the analyst and broker recommendations for Dexcom Inc?

Of the analysts with advisory recommendations for Dexcom Inc, there are there are currently 11 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Dexcom Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Dexcom Inc next release its financial results?

Dexcom Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Dexcom Inc dividend yield?

Dexcom Inc does not currently pay a dividend.

Does Dexcom Inc pay a dividend?

Dexcom Inc does not currently pay a dividend.

When does Dexcom Inc next pay dividends?

Dexcom Inc does not currently pay a dividend.

How do I buy Dexcom Inc shares?

To buy shares in Dexcom Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Dexcom Inc?

Shares in Dexcom Inc are currently trading at $388.5, giving the company a market capitalisation of £27.25bn.

Where are Dexcom Inc shares listed? Where are Dexcom Inc shares listed?

Here are the trading details for Dexcom Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: DXCM
What kind of share is Dexcom Inc?

Based on an overall assessment of its quality, value and momentum, Dexcom Inc is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Dexcom Inc share price forecast 2021?

Shares in Dexcom Inc are currently priced at $388.5. At that level they are trading at 20.77% discount to the analyst consensus target price of 0.00.

Analysts covering Dexcom Inc currently have a consensus Earnings Per Share (EPS) forecast of 2.373 for the next financial year.

How can I tell whether the Dexcom Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Dexcom Inc. Over the past six months, the relative strength of its shares against the market has been -17.1%. At the current price of $388.5, shares in Dexcom Inc are trading at 0.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Dexcom Inc PE Ratio?

The Dexcom Inc PE ratio based on its reported earnings over the past 12 months is 72.29. The shares are currently trading at $388.5.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Dexcom Inc?

Dexcom Inc's management team is headed by:

Andrew Balo - EVP
Steven Pacelli - EVP
Kevin Sayer - CHM
Jeffrey Moy - SVP
Nicholas Augustinos - IND
Steven Altman - IND
Mark Foletta - LED
Richard Collins - IND
Donald Abbey - EVP
Jake Leach - EVP
Patrick Murphy - EVP
Quentin Blackford - COO
Jereme Sylvain - CFO
Shelly Selvaraj - SVP
Karen Dahut - IND
Who are the major shareholders of Dexcom Inc?

Here are the top five shareholders of Dexcom Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 10.64% (10.2m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 7.11% (6.84m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 5.67% (5.45m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 5.08% (4.89m shares)
State Street Global Advisors (US) Investment Advisor/Hedge Fund
Percentage owned: 4.02% (3.86m shares)
Similar to DXCM
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.